Search results
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 4 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
How Long Does Carpal Tunnel Syndrome Usually Last? A Review By Doctors
MSN News· 6 days agoExpert opinion from Marcelle Freire Doctor of Medicine · 3 years of experience · Brazil Carpal...
Research shows linked biological pathways driving skin inflammation
Medical Xpress· 4 days agoLed by researchers at NYU Langone Health, the new study found that the interleukin-17 (IL-17)...
Tracking down the genetic causes of lupus to personalize treatment
Medical Xpress· 24 hours agoResearchers are just now beginning to link specific genetic mutations to subsets of lupus patients, allowing physicians to target therapies to those who will benefit most. In the latest advance ...
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Motley Fool via Yahoo Finance· 4 days agoLuckily, sales of Rinvoq, an arthritis tablet, and Skyrizi, a psoriasis injection, offset the loss....
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? | The Motley...
The Motley Fool· 4 days agoWall Street is feeling pretty good about AbbVie's (ABBV -1.19%) performance in 2024 so far. Chen...
Do LED Skin-Care Devices Even Work?
New York Magazine· 3 days agoLight therapy via at-home LED (light-emitting diodes) devices is trending in skin care right now, but it’s not just a fad. According to Dr. Jared Jagdeo,...
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
KTLA-TV Los Angeles· 1 day agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
WKRN Nashville· 1 day agoIn these studies, bimekizumab consistently demonstrated sustained improvements...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 2 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...